1. Group 4
Gaps & obstacles

2. How do we better utilize what we already have
How do we better utilize what we already have? Anything that simplifies will help
Outcomes research of current practice e.g.
Where adult FDC already in use in children
Approximation of doses to accommodate solid formulations

3. Research needs (1) pK Simplified dosing regimens Age
Mg/kg versus BSA
Rounding off of doses
Use of adult formulations
Age
Nutritional status
Include the effect of changing status on dosage e.g. marasmic infant
Genetics

4. Research needs (2) pK (continued) Specific drug-related questions ddI
Daily vs bid
Food with admin
2 tablets for buffering?
NVP & 3TC
Clarify dose
EFV < 3y or 10kg

5. Longitudinal outcome cohorts in resource-constrained settings “Post marketing surveillance”
Adherence in children
What is the best approach
What intensity?
Systems for surveillance
Clinical outcome
Resistance
Toxicity
Program evaluation

6. PMTCT interventions FDCs must reflect resistance concerns
Mother & infant